In a report released yesterday, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie (ABBV – Research Report), with a price target of ...
BMO Capital analyst Evan Seigerman raised the firm’s price target on AbbVie (ABBV) to $215 from $208 and keeps an Outperform rating on the ...
AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq by $4 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback